BiotechTube

burosumab + Oral Phosphate Supplement + active vitamin D

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-Linked Hypophosphatemia

Conditions

X-Linked Hypophosphatemia

Trial Timeline

Sep 8, 2016 → Jul 15, 2019

NCT ID
NCT02915705

About burosumab + Oral Phosphate Supplement + active vitamin D

burosumab + Oral Phosphate Supplement + active vitamin D is a phase 3 stage product being developed by Kyowa Kirin for X-Linked Hypophosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02915705. Target conditions include X-Linked Hypophosphatemia.

What happened to similar drugs?

2 of 7 similar drugs in X-Linked Hypophosphatemia were approved

Approved (2) Terminated (0) Active (5)
🔄KRN23Kyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3
✅KRN23Kyowa KirinApproved
🔄BurosumabKyowa KirinPhase 3
🔄BurosumabKyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3
✅KRN23Kyowa KirinApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02915705Phase 3Completed

Competing Products

20 competing products in X-Linked Hypophosphatemia

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
26
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
39
BurosumabKyowa KirinPhase 1/2
32
BurosumabKyowa KirinPre-clinical
30
BurosumabKyowa KirinPre-clinical
26
BurosumabKyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1/2
32
KRN23Kyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinApproved
43
burosumabKyowa KirinPhase 2
35
BurosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 1/2
32
Placebo + KRN23Kyowa KirinPhase 1
29
BurosumabKyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1
29
KRN23Kyowa KirinApproved
43
KK8123Kyowa KirinPhase 1/2
39